Skip to Main content Skip to Navigation
Journal articles

Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study

Pieternella Lugtenburg Irit Avivi 1 Henriette Berenschot Osman Ilhan Jean Pierre Marolleau 2 Arnon Nagler 3 Antonio Rueda Monica Tani Mehmet Turgut Stuart Osborne Rodney Smith Michael Pfreundschuh 4 Adrian Tempescul 5 
1 Tel Aviv Sourasky Medical Center [Te Aviv]
2 CHU Amiens-Picardie
3 CHU Saint-Antoine [AP-HP]
4 Saarland University Medical School
5 CIC Brest
Document type :
Journal articles
Complete list of metadata
https://hal.univ-brest.fr/hal-02049783
Contributor : Ghislaine Calvez Connect in order to contact the contributor
Submitted on : Tuesday, February 26, 2019 - 4:10:29 PM
Last modification on : Thursday, August 4, 2022 - 5:25:55 PM

Identifiers

  • HAL Id : hal-02049783, version 1

Collections

UNIV-BREST | SORBONNE-UNIVERSITE | SU-MEDECINE

Citation

Pieternella Lugtenburg, Irit Avivi, Henriette Berenschot, Osman Ilhan, Jean Pierre Marolleau, et al.. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica, Ferrata Storti Foundation, 2017, 102 (11), pp.1913-1922. ⟨hal-02049783⟩

Export

BibTeX TEI DC DCterms EndNote Datacite

Share

Metrics

Record views

16